Alzheimer’s drug slows cognitive decline
Eisai and Biogen's experimental Alzheimer's disease medicine slows cognitive decline in a rigorously monitored trial, but it may pose a risk of dangerous side effects for certain patients, according to the recent results presented. Lecanemab was linked to a sort of brain enlargement in 12.6% of